Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/2854
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorGIAVINA-BIANCHI, Mara-
dc.contributor.authorSOTTO, Miriam Nacagamo-
dc.contributor.authorKANASHIRO, Luciane-
dc.contributor.authorSIMPSON, Andrew J.-
dc.contributor.authorGIAVINA-BIANCHI, Pedro-
dc.contributor.authorKALIL, Jorge-
dc.contributor.authorFESTA, Cyro-
dc.date.accessioned2013-10-11T21:19:04Z-
dc.date.available2013-10-11T21:19:04Z-
dc.date.issued2013-
dc.identifier.citationJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, v.131, n.2, suppl.S, p.AB66-AB66, 2013-
dc.identifier.issn0091-6749-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2854-
dc.description.abstractRATIONALE: It is important to study the expression of cancer-testis antigens such as NY-ESO-1, because they can help not only in diagnosis, but can be a very interesting target for immunotherapy against cancer. The aim of this study was to correlate the expression of cancer-testis antigen NY-ESO-1 with morbidity and mortality of cutaneous melanoma. METHODS: This was a retrospective cohort with 471 patients. They were separated in three groups: 1-Thinmelanoma (in situ or thickness < 1.1mm); 2- Intermediate (from 1.1 to 4.0mm); and 3- Thick tumors (> 4.0mm). We randomly sortedout 31,28and31casesfromgroups1,2and3,respectively, totalizing 90 melanoma cases. The patients’ charts were reviewed, and the clinicopathological parameters analyzed. The tumor specimens were also reviewed and subsequently subjected to immunohistochemical examination to study the expression of tumor protein NY-ESO-1. RESULTS: Therewas no statistical difference between groups NY-ESO-1 positive (25% of cases) and negative (75% of cases) with respect to gender, race, skin type, age, tumor location, pre-existing lesion, histological type, Breslow index, ulceration, sentinel lymph node, metastases development and survival rates. Melanomas NY-ESO-1 positivewere on average thicker than the negative ones (p 50.026). CONCLUSIONS: Immunohistochemistry with antibodies NY-ESO-1 was positive in 25% of melanom’s biopsy specimens. The expression of NY-ESO-1 was associated with tumor thickness, but not mortality from melanoma.-
dc.language.isoeng-
dc.publisherMOSBY-ELSEVIER-
dc.relation.ispartofJournal of Allergy and Clinical Immunology-
dc.rightsrestrictedAccess-
dc.titleNY-ESO-1 Expression Is Associated with Melanoma Thickness, but Not Mortality-
dc.typeconferenceObject-
dc.rights.holderCopyright MOSBY-ELSEVIER-
dc.description.conferencedateFEB 22-26, 2013-
dc.description.conferencelocalSan Antonio - TX, EUA-
dc.description.conferencenameAnnual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI)-
dc.subject.wosAllergy-
dc.subject.wosImmunology-
dc.type.categorymeeting abstract-
dc.type.versionpublishedVersion-
hcfmusp.author.externalSIMPSON, Andrew J.:Ludwig Inst Canc Res, Sao Paulo, Brazil-
hcfmusp.description.beginpageAB66-
hcfmusp.description.endpageAB66-
hcfmusp.description.issue2-
hcfmusp.description.issuesuppl S-
hcfmusp.description.volume131-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000316550800240-
hcfmusp.publisher.cityNEW YORK-
hcfmusp.publisher.countryUSA-
dc.description.indexMEDLINE-
Appears in Collections:

Comunicações em Eventos - FM/MCM
Departamento de Clínica Médica - FM/MCM

Comunicações em Eventos - FM/MDT
Departamento de Dermatologia - FM/MDT

Comunicações em Eventos - HC/ICHC
Instituto Central - HC/ICHC

Comunicações em Eventos - HC/InCor
Instituto do Coração - HC/InCor

Comunicações em Eventos - LIM/19
LIM/19 - Laboratório de Histocompatibilidade e Imunidade Celular

Comunicações em Eventos - LIM/53
LIM/53 - Laboratório de Micologia

Comunicações em Eventos - LIM/60
LIM/60 - Laboratório de Imunologia Clínica e Alergia


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.